Results 331 to 340 of about 182,855 (396)

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

open access: yesScience Translational Medicine, 2019
In the VANILLA phase 2 clinical trial, balovaptan treatment resulted in improved adaptive behaviors in adult men with autism. Modulating vasopressin in ASD The neuropeptide vasopressin has been implicated in the regulation of social behaviors in animals ...
Federico Bolognani   +2 more
exaly   +2 more sources
Some of the next articles are maybe not open access.

Related searches:

Vasopressin

Seminars in Respiratory and Critical Care Medicine, 2004
Vasopressin is a hormone that is essential for both osmotic and cardiovascular homeostasis. A deficiency of vasopressin exists in some shock states and replacement of physiological levels of vasopressin can restore vascular tone. Vasopressin is therefore emerging as a rational therapy for vasodilatory shock.
Cheryl L, Holmes, James A, Russell
openaire   +2 more sources

Effect of exogenous vasopressin on vasopressin release

American Journal of Physiology-Endocrinology and Metabolism, 1984
To characterize the influence of extracellular volume status on vasopressin pharmacokinetics, eleven young (aged 19-31 yr) and four old (aged 62-80 yr) subjects received bolus injections of 1 mU/kg Pitressin or synthetic arginine vasopressin following 6 days of sodium depletion (10 meq Na/day) or sodium loading (250 meq Na/day).
G. L. Robertson   +3 more
openaire   +3 more sources

Vasopressin: physiology, assessment and osmosensation

open access: yesJournal of Internal Medicine, 2017
Lise Bankir   +3 more
exaly   +2 more sources

Oxytocin, vasopressin, and human social behavior

open access: yesFrontiers in Neuroendocrinology, 2009
Bernadette von Dawans, Gregor Domes
exaly   +2 more sources

Vasopressin and vasopressin receptors in brain edema

2020
Vasopressin is a peptide hormone produced in the hypothalamus and released from the posterior pituitary. Secretion of vasopressin is followed by activation of its receptors V1a, V1b, and V2 throughout the body. Each receptor type is responsible for a specific function of vasopressin.
J Paul Elliott   +2 more
openaire   +2 more sources

Biosynthesis of Vasopressin

Journal of Cardiovascular Pharmacology, 1986
The nonapeptide vasopressin is synthetized as part of a longer common precursor polypeptide, together with its carrier protein neurophysin and a glycopeptide of unknown function. The gene for this common precursor has been isolated and sequenced and shown to comprise three exons encoding, respectively, the protein domains approximately corresponding to
Dietmar Richter   +2 more
openaire   +3 more sources

Vasopressin and Vasopressin Antagonists in Heart Failure

2017
Despite the introduction of multiple new pharmacological agents over the past three decades in the field of heart failure (HF), overall prognosis remains poor. Hyponatremia is prevalent in HF patients and has been suggested as a contributor to poor response to standard therapy.
Finn Gustafsson   +1 more
openaire   +3 more sources

Vasopressin antagonists

Cellular and Molecular Life Sciences, 2006
Effects of vasopressin via V1a- and V2-receptors are closely implicated in a variety of water-retaining diseases and cardiovascular diseases, including heart failure, hyponatraemia, hypertension, renal diseases, syndrome of inappropriate antidiuretic hormone secretion, cirrhosis and ocular hypertension.
Lemmens, Rosa, Kamyar, Majid-Reza
openaire   +2 more sources

Home - About - Disclaimer - Privacy